UnitedHealth Group (NYSE:UNH | UNH Price Prediction) shares rose 7.3% over the past week as retail investor sentiment on Reddit and X shifted from deeply bearish to neutral. Trading around $355, the stock has stabilized after falling significantly from its 52-week high following the December 2024 shooting of UnitedHealthcare CEO Brian Thompson. Current sentiment scores sit at 42 out of 100, up from extreme negativity just months ago.

From Most Hated to Neutral Ground
UNH mentions on Reddit showed dramatic volatility over four months, with sentiment swinging from 18 on r/WallStreetBets in November to bullish peaks of 82 in late December. Reddit discussions showed significant engagement with mixed sentiment across different communities. Today, activity has cooled but tone shifted from hostile to cautiously neutral.
Subreddit communities diverged sharply. WallStreetBets remained bearish during high-activity periods, while r/options maintained bullish sentiment. A recurring post titled “Option trade I made with UNH” saw engagement climb from 12 to 24 upvotes over 27 hours in late January, detailing a trader’s deep in-the-money call position that lost nearly $3,000 when the stock tanked to $310 but has since recovered.
Option trade I made with UNH
by u/Confident_Mousse_166 in options
Factors supporting neutral positioning:
- Berkshire Hathaway’s 5 million share position provides institutional validation
- Options traders consistently showed confidence with LEAPS discussions and deep ITM call positions
- Stock trades near 50-day ($331) and 200-day ($338) averages
Peer Comparison and Path Forward
Cigna (NYSE:CI) recently reported Q3 revenue of $69.7 billion, up 10% year-over-year, demonstrating managed healthcare companies can still deliver growth despite sector headwinds. Cigna trades at a P/E of 12 compared to UNH’s 18, though both face similar margin pressures and regulatory scrutiny.
UnitedHealth’s sentiment recovery from 30 in late September to 42 today represents 40% improvement, though well below December’s bullish peaks of 82. With analyst price targets at $394 (11% upside) and the stock showing recent gains after a substantial decline over the past year, retail sentiment has stabilized at neutral as the company works to move past one of healthcare’s darkest chapters.